FIELD: medicine.
SUBSTANCE: claimed invention relates to medicine, in particular to materials permitting to stop hemorrhage during operational intrusions. Material contains thrombocyte concentrate unsuitable for transfusion, cryoprecipitate of blood plasma proteins in ratio 1:1, as well as calcium chloride in amount 0.05 ml per 1 ml of mixture of thrombocyte concentrate with cryoprecipitate and thrombin in amount 0.01 NIH units per 1 ml of mixture of thrombocyte concentrate with cryoprecipitate.
EFFECT: claimed invention ensures increase of concentration of blood coagulation activators and factors in hemostatic material in order to increase its hemotatic activity.
Title | Year | Author | Number |
---|---|---|---|
HEMOSTATIC MATERIAL | 2005 |
|
RU2287333C1 |
ORGAN-SPECIFIC REGENERANT GI | 2011 |
|
RU2462255C1 |
HAEMOSTATIC SPONGE AND METHOD FOR ITS PREPARATION | 2016 |
|
RU2618896C1 |
HEMOSTATIC COATING IN THE FORM OF POWDER | 2017 |
|
RU2660582C1 |
HAEMOSTATIC SPONGE | 2011 |
|
RU2562569C2 |
HEMOSTATIC SPONGE AND METHOD OF ITS PRODUCTION | 2016 |
|
RU2628809C1 |
METHOD OF DETERMINING INDICATIONS FOR TRANSFUSION OF PLASMA-COAGULATION HAEMOSTASIS CORRECTORS IN CARDIAC SURGERY | 2014 |
|
RU2568581C1 |
METHOD FOR ENDOSCOPIC STOP OF GASTROINTESTINAL BLEEDING | 2016 |
|
RU2632771C1 |
METHOD OF PREPARATION OF AUTOLOGOUS TWO-COMPONENT FIBRIN ADHESIVE | 2019 |
|
RU2704256C1 |
FACTOR II AND FIBRINOGEN FOR TREATMENT OF HAEMOSTATIC DISORDERS | 2011 |
|
RU2606155C2 |
Authors
Dates
2009-05-10—Published
2008-02-19—Filed